Duell publishes its business review for Q3 (March-May) on Wednesday 3rd of July.
Redeye initiates coverage of Nekkar, an industrial technology group offering ocean-based technologie...
Redeye comments on the continued expansion into California with a new collaboration with United Heal...
Q2 report due Tuesday, 23 July – many moving parts Key factor looks to be possible imminent Medicare...
22% sales growth (ABGSCe +24%), losses to gradually improve EBIT ests roughly unchanged, 5-8% margin...
Redeye comments on Medivir’s update from ESMO GI, showing improvements in fostrox’ TTP.
Yesterday evening, Hoylu communicated that a number of shareholders in the Company, including board ...
PMDS has revised the 2026 sales target, which is 160% higher at SEK 260m (SEK 100m) in terms of recu...
Redeye initiates coverage of CTEK, a market leader within premium low-voltage chargers that is lever...
Yesterday (25 June) we hosted a group presentation with Ferronordic.
Q2e: 6% organic sales growth y-o-y, 9% adj. EBITA margin Expect a softer Q2, partly on further marke...
Redeye leaves a comment following today’s announcement of the outcome of Alzinova’s recent rights is...
Redeye comments on the outcome of the T02 and the directed issue to the top guarantors, which brough...
Redeye provides a comment on the outcome in Respiratorius’ rights issue, announced earlier this afte...
Redeye comments on Truecaller ahead of its Q2 results, which are due on 19 July.
